Shots:

• The P-I/II (TORCH-2) study evaluating ATG-008 + toripalimab in 60 patients with relapsed/metastatic cervical cancer
• The results showed an ORR (52.4%) in the combination therapy & 77.8% for PD-L1+ patients & 1 out of 2 CPI-exposed patients reached PR with manageable side effects, similar to observations in prior global studies. The results were built from the early data from 21 patients, incl. 10 with PR & 1 with CR, 9 out of 10 were still responding, 2 with SD were still on treatment, m-PFS (5.5mos.)
• The (TORCH) study in patients with HBV+ unresectable HCC showed ORR (16.7%) in the 45mg/day dosing cohort; 3 with confirmed PRs out of 18 patients, m-DoR (4.3mos.), 2 out of 3 with PRs prior treated with PD-1/PD-L1 Ab

Ref: Antengene   | Image: Antengene